Literature DB >> 12911582

Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?

S A Brown1, A Eldridge, P W Collins, D J Bowen.   

Abstract

The mechanism of von Willebrand factor (VWF) clearance is not fully understood. The factors that affect VWF clearance, and the normal in vivo mechanism of clearance, may be relevant to the pathogenesis of Type 1 von Willebrand disease (VWD), in which there is a partial deficiency of VWF. In order to investigate the clearance of VWF in Type 1 VWD, the current study assessed the half-life of VWF antigen (t(1/2) VWF:Ag) in Type 1 VWD patients and individuals with mild hemophilia A following the administration of 1-deamino-8-d-arginine vasopressin (DDAVP; desmopressin). To date 20 individuals have been assessed, 13 with Type 1 VWD and seven with mild hemophilia A. The median t(1/2) VWF:Ag in the Type 1 VWD and mild hemophilia A groups were 4.6 h and 9.5 h, respectively. The difference between the t(1/2) VWF:Ag for the two groups was significant, P < 0.02. Analysis of the data showed a correlation between the t(1/2) VWF:Ag and the baseline VWF:Ag level prior to administration of DDAVP: lower baseline VWF:Ag levels were associated with a shorter t(1/2) VWF:Ag. These data suggest that increased clearance of VWF may be the pathogenic mechanism in some cases of Type 1 VWD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911582     DOI: 10.1046/j.1538-7836.2003.00359.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

1.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Authors:  Heidi L Lemmerhirt; Jordan A Shavit; Gallia G Levy; Suzanne M Cole; Jeffrey C Long; David Ginsburg
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

2.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

3.  Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.

Authors:  Q Shi; E L Kuether; J A Schroeder; S A Fahs; R R Montgomery
Journal:  Haemophilia       Date:  2012-01-04       Impact factor: 4.287

Review 4.  Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians.

Authors:  Radha Mehta; Muhammad Athar; Sameh Girgis; Atif Hassan; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2019-07       Impact factor: 2.300

5.  Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

Authors:  A Gézsi; U Budde; I Deák; E Nagy; A Mohl; A Schlammadinger; Z Boda; T Masszi; J E Sadler; I Bodó
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

6.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

7.  Treatment of patients with von Willebrand disease.

Authors:  Emma Tuohy; Emma Litt; Raza Alikhan
Journal:  J Blood Med       Date:  2011-04-20

Review 8.  Of von Willebrand factor and platelets.

Authors:  Marijke Bryckaert; Jean-Philippe Rosa; Cécile V Denis; Peter J Lenting
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

9.  Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications.

Authors:  Massimo Franchini; Franco Capra; Giovanni Targher; Martina Montagnana; Giuseppe Lippi
Journal:  Thromb J       Date:  2007-09-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.